Eman Badr1, Eman Masoud2, Asmaa Gaber Abdou3, Marwa Serag Eldien4. 1. Assistant Professor, Department of Biochemistry, Shebein Elkom , Menoufia, Egypt . 2. Lecturer, Department of Biochemistry, Shebein Elkom , Menoufia, Egypt . 3. Professor, Department of Pathology, Shebein Elkom , Menoufia, Egypt . 4. Lecturer, Department of Pathology, Shebein Elkom , Menoufia, Egypt .
Abstract
INTRODUCTION: B-Cell Lymphoma 6 (BCL6) has an oncogenic role in tumourigenesis of various malignancies. It represses genes involved in terminal differentiation and plays complementary role with Signal Transducer and Activator of Transcription 3 (STAT3) in triple-negative breast cancer cellular function. AIM: To evaluate the expression of BCL6 in cancer breast and determine its correlation with the clinico-pathological features including the molecular subtype of breast carcinoma. MATERIALS AND METHODS: This prospective case control study was carried out on 150 patients, divided into 100 cases of invasive duct carcinoma not otherwise specified and 50 benign breast lesions including fibroadenoma and fibrocystic disease. Fresh tissues were excised, which were then subjected to RNA extraction. The BCL6 mRNA level was assessed using real-time reverse transcription Polymerase Chain Reaction (PCR). RESULTS: There was a significant higher levels of BCL6 mRNA in malignant cases compared to benign ones (p<0.001). The level of BCL6 mRNA was higher in cases showing advanced tumor stage (p<0.04), triple negative subtype and associated in situ component (p<0.001) compared to cases with an early stage, luminal or Her 2-neu positive subtypes and those lacking in situ component. CONCLUSION: BCL6 is up-regulated in breast cancer and is associated with poor prognostic features such as advanced stage and triple negative molecular subtype. BCL6 inhibitors might be considered as targeted therapy for breast cancer.
INTRODUCTION:B-Cell Lymphoma 6 (BCL6) has an oncogenic role in tumourigenesis of various malignancies. It represses genes involved in terminal differentiation and plays complementary role with Signal Transducer and Activator of Transcription 3 (STAT3) in triple-negative breast cancer cellular function. AIM: To evaluate the expression of BCL6 in cancer breast and determine its correlation with the clinico-pathological features including the molecular subtype of breast carcinoma. MATERIALS AND METHODS: This prospective case control study was carried out on 150 patients, divided into 100 cases of invasive duct carcinoma not otherwise specified and 50 benign breast lesions including fibroadenoma and fibrocystic disease. Fresh tissues were excised, which were then subjected to RNA extraction. The BCL6 mRNA level was assessed using real-time reverse transcription Polymerase Chain Reaction (PCR). RESULTS: There was a significant higher levels of BCL6 mRNA in malignant cases compared to benign ones (p<0.001). The level of BCL6 mRNA was higher in cases showing advanced tumor stage (p<0.04), triple negative subtype and associated in situ component (p<0.001) compared to cases with an early stage, luminal or Her 2-neu positive subtypes and those lacking in situ component. CONCLUSION:BCL6 is up-regulated in breast cancer and is associated with poor prognostic features such as advanced stage and triple negative molecular subtype. BCL6 inhibitors might be considered as targeted therapy for breast cancer.
Authors: Jose M Polo; Przemyslaw Juszczynski; Stefano Monti; Leandro Cerchietti; Kenny Ye; John M Greally; Margaret Shipp; Ari Melnick Journal: Proc Natl Acad Sci U S A Date: 2007-02-20 Impact factor: 11.205
Authors: Weimin Ci; Jose M Polo; Leandro Cerchietti; Rita Shaknovich; Ling Wang; Shao Ning Yang; Kenny Ye; Pedro Farinha; Douglas E Horsman; Randy D Gascoyne; Olivier Elemento; Ari Melnick Journal: Blood Date: 2009-03-23 Impact factor: 22.113
Authors: Jaye M Stapleton; Patricia B Mullan; Subhojit Dey; Ahmed Hablas; Rabab Gaafar; Ibrahim A Seifeldin; Mousumi Banerjee; Amr S Soliman Journal: Psychooncology Date: 2011-05 Impact factor: 3.894
Authors: Sarah R Walker; Erik A Nelson; Lihua Zou; Mousumi Chaudhury; Sabina Signoretti; Andrea Richardson; David A Frank Journal: Mol Cancer Res Date: 2009-06-02 Impact factor: 5.852